May 21, 2024
Trypsin Market

Trypsin Market Driven By Increasing R&D In Biopharmaceutical Sector Is Estimated To Generate Revenue Opportunities

Trypsin is a pancreatic endopeptidase enzyme that helps in protein digestion by catalyzing the hydrolysis of peptides and polypeptides present in small intestine. It is commonly used as cell culture reagent for dissociating and detaching adherent cells from the surface of reactors, flasks or other laboratory equipment. Significant growth in biopharmaceutical research and rising investment in development of new biologics have augmented the demand for trypsin as a cell detachment agent in cell-based assays.

The global Trypsin Market is estimated to be valued at US$ 46.72 Million in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key Trends:

One of the major trends gaining traction in the trypsin market is increasing outsourcing of biopharmaceutical production. Numerous biopharmaceutical companies are outsourcing bulk production to large contract development and manufacturing organizations (CDMOs) with extensive expertise and infrastructure. For instance, Biologics manufacturing requiring trypsin during various stages represents significant capital expenditure and specialized personnel. This has encouraged small and mid-sized biologics developers as well as big pharmaceutical firms to partner with CDMOs which can support manufacturing on fee-for-service basis. Scale of outsourcing is growing steadily which in turn is propelling the demand for trypsin in commercial production of biologics.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the trypsin market is moderately high due to significant capital requirements and established brand loyalty. However, opportunities exist for specialized products.
Bargaining power of buyers: The bargaining power of buyers in the trypsin market is high due to the availability of substitute products. Buyers can switch to alternative products if pricing increases.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are many suppliers in the market and suppliers do not have the capability to impact pricing.
Threat of new substitutes: The threat of new substitutes is moderate as alternative products are available in the market. However, trypsin offers certain unique functionality.
Competitive rivalry: The competitive rivalry in the trypsin market is high due to the presence of established brands. Companies compete based on pricing and product differentiation.

Key Takeaways

The global Trypsin Market Growth is estimated to be valued at US$ 46.72 Million in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2030.

The global trypsin market is expected to witness high growth over the forecast period. The market is dominated by North America currently and is expected to remain the largest market during the forecast period. Asia Pacific is expected to grow at the fastest pace in the trypsin market during the forecast period due to improving access to healthcare facilities and rapidly developing pharmaceutical industry.

Key players: Key players operating in the trypsin market are Pfizer, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Bayer AG, Astrazeneca, and Sanofi. Key players compete based on strong distribution network, wide product portfolio, and brand positioning.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it